Treatment options for advanced pancreatic cancer: a review

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA. Cancer J. Clin. 60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Syrigos KN, Saif MW. Translational research in pancreatic cancer. Highlights from the ‘2010 ASCO Gastrointestinal Cancers Symposium’. Orlando, FL, USA. January 22–24, 2010. JOP 11(2), 124–127 (2010).
   Google Scholar
• Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 363(9414), 1049–1057 (2004).
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817–1825 (2011).
   PubMed Web of Science ®Google Scholar
• Callery MP, Chang KJ, Fishman EK et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann. Surg. Oncol. 16(7), 1727–1733 (2009).
   PubMed Web of Science ®Google Scholar
• Bao PQ, Johnson JC, Lindsey EH et al. Endoscopic ultrasound and computed tomography predictors of pancreatic cancer resectability. J. Gastrointest. Surg. 12(1), 10–6; discussion 16 (2008).
   Google Scholar
• Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48(8), 1705–1710 (1981).
   PubMed Web of Science ®Google Scholar
• Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP 8(3), 279–288 (2007).
   Google Scholar
• Cohen SJ, Dobelbower R Jr, Lipsitz S et al. Eastern Cooperative Oncology Group. A randomized Phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int. J. Radiat. Oncol. Biol. Phys. 62(5), 1345–1350 (2005).
   Google Scholar
• Ben-Josef E, Shields AF, Vaishampayan U et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 59(2), 454–459 (2004).
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res. 5(10), 2948–2953 (1999).
   PubMed Web of Science ®Google Scholar
• Kim HS, Yi SY, Jun HJ et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. Anticancer. Drugs 21(1), 107–112 (2010).
   Google Scholar
• Yi S, Kim HS, Lee J et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. 27(15) (2009).
   Google Scholar
• Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 21(18), 3402–3408 (2003).
   PubMedGoogle Scholar
• Mornex F, Girard N, Bossard N, Ychou M, Chauffert B, Wautot V. estimating optimal dose of twice weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of gemrt-01 Phase I trial. Int. J. Radiat. Oncol. 77(5), 1426–1432 (2010).
   Google Scholar
• Murphy JD, Normolle D, Adusumilli S et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer: analysis of toxicity. Int. J. Radiat. Oncol. 66(3), S265–S266 (2006).
   Google Scholar
• Loehrer PJ Sr, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 29(31), 4105–4112 (2011).
   PubMed Web of Science ®Google Scholar
• Crane CH, Abbruzzese JL, Evans DB et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1293–1302 (2002).
   Google Scholar
• Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71(12), 1171–1177 (1987).
   PubMedGoogle Scholar
• Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 22(3), 613–617 (1992).
   Google Scholar
• Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2(1), 72–79 (1996).
   PubMed Web of Science ®Google Scholar
• Rich T, Harris J, Abrams R et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am. J. Clin. Oncol. 27(1), 51–56 (2004).
   Google Scholar
• Haddock MG, Swaminathan R, Foster NR et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J. Clin. Oncol. 25(18), 2567–2572 (2007).
   Google Scholar
• Talamonti MS, Catalano PJ, Vaughn DJ et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.J. Clin. Oncol. 18(19), 3384–3389 (2000).
   PubMed Web of Science ®Google Scholar
• Hong TS, Chen RC, Mamon HJ et al. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer 116(8), 1879–1886 (2010).
   Google Scholar
• Mamon HJ, Niedzwiecki D, Hollis D et al. A Phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma. Cancer 117(12), 2620–2628 (2011).
   Google Scholar
• Park JO, Kim HS, Yi SY et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. Anticancer Drugs 21(1), 107–112 (2010).
   Google Scholar
• Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 19(9), 1592–1599 (2008).
   PubMed Web of Science ®Google Scholar
• Brunner TB, Grabenbauer GG, Kastl S et al. Preoperative chemoradiation in locally advanced pancreatic carcinoma: a Phase II study. Onkologie 23(5), 436–442 (2000).
   Google Scholar
• Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 27(23), 3778–3785 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430–1438 (2004).
   PubMed Web of Science ®Google Scholar
• Hu J, Zhao G, Wang HX et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J. Hematol. Oncol. 4 doi:10.1186/1756-8722-4-11 (2011) (Epub ahead of print).
   Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Birk D, Gansauge F, Gansauge S, Formentini A, Lucht A, Beger HG. Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int. J. Pancreatol. 25(2), 89–96 (1999).
   Google Scholar
• Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother. Pharmacol. 54(Suppl. 1), S69–S77 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27(33), 5513–5518 (2009).
   PubMed Web of Science ®Google Scholar
• Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol. 25(18), 2607–2615 (2007).
   PubMed Web of Science ®Google Scholar
• Boeck S, Vehling-Kaiser U, Waldschmidt D et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over Phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs 21(1), 94–100 (2010).
   Google Scholar
• Ychou M, Conroy T, Seitz JF et al. An open Phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann. Oncol. 14(3), 481–489 (2003).
   Google Scholar
• Conroy T, Paillot B, François E et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. 23(6), 1228–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a Phase III study from the German CONKO-study group. Eur. J. Cancer 47(11), 1676–1681 (2011).
   PubMed Web of Science ®Google Scholar
• Ko AH, Tempero MA, Shan Y et al. A multinational Phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer. 2011 Gastrointestinal Cancers Symposium. J. Clin. Oncol. 29(Suppl. 4), abstract 237 (2011).
   Google Scholar
• Makrilia N, Syrigos KN, Saif MW. Treatment for refractory pancreatic cancer. Highlights from the ‘2011 ASCO Gastrointestinal Cancers Symposium’ San Francisco, CA, USA. January 20–22, 2011. JOP 12(2), 110–113 (2011).
   Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J. Clin. Oncol. 29(34), 4548–4554 (2011).
   PubMed Web of Science ®Google Scholar
• Garber K. Improved Paclitaxel formulation hints at new chemotherapy approach. J. Natl. Cancer Inst. 96(2), 90–91 (2004).
   Google Scholar
• Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4), 549–554 (1988).
   PubMed Web of Science ®Google Scholar
• Bodoky G, Timcheva C, Spigel DR et al. A Phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. New Drugs 30(3), 1216–1223 (2012).
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Liu W, Reinmuth N et al. Regulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 163(3), 1001–1011 (2003).
   Google Scholar
• Moser C, Schachtschneider P, Lang SA et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur. J. Cancer 44(11), 1577–1586 (2008).
   Google Scholar
• García-Echeverría C, Pearson MA, Marti A et al. In vivo anti-tumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5(3), 231–239 (2004).
   PubMed Web of Science ®Google Scholar
• Burtrum D, Zhu Z, Lu D et al. A fully human monoclonal antibody to the insulin-like growth factor-I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63(24), 8912–8921 (2003).
   PubMedGoogle Scholar
• Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 63(3), 627–635 (2003).
   Google Scholar
• Long J, Zhang Y, Yu X et al. Overcoming drug resistance in pancreatic cancer. Expert Opin. Ther. Targets 15(7), 817–828 (2011).
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Marten A, Lindel K et al. Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon α: report on several cases and review of the literature [ISRCTN62866759]. BMC Cancer 6, 128 (2006).
   PubMedGoogle Scholar
• Banerjee S, Wang Z, Kong D, Sarkar FH. 3,3´-diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 69(13), 5592–5600 (2009).
   Google Scholar
• Ellenrieder V, Hendler SF, Boeck W et al. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61(10), 4222–4228 (2001).
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457–1461 (2009).
   PubMed Web of Science ®Google Scholar
• Yauch RL, Gould SE, Scales SJ et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455(7211), 406–410 (2008).
   PubMed Web of Science ®Google Scholar
• Kelleher FC. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 32(4), 445–451 (2011).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Schüll B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol. 14(1), 97–104 (2003).
   PubMed Web of Science ®Google Scholar
• Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20(15), 3270–3275 (2002).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Labianca R, Bodoky G et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27(19), 3117–3125 (2009).
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P et al. GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23(15), 3509–3516 (2005).
   PubMed Web of Science ®Google Scholar
• Colucci G, Labianca R, Di Costanzo F et al.; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized Phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 28(10), 1645–1651 (2010).
   PubMed Web of Science ®Google Scholar
• Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 94(4), 902–910 (2002).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24(24), 3946–3952 (2006).
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Syrigos K, Aravantinos G et al. A multicenter Phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br. J. Cancer 95(5), 587–592 (2006).
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18), 3776–3783 (2004).
   Google Scholar
• Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 16(10), 1639–1645 (2005).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Letourneau R, Harker G et al. Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 24(27), 4441–4447 (2006).
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 28(22), 3605–3610 (2010).
   PubMed Web of Science ®Google Scholar
• Saif MW, Oettle H, Vervenne WL et al. Randomized double-blind Phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J. 15(4), 339–343 (2009).
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87(2), 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28(22), 3617–3622 (2010).
   PubMed Web of Science ®Google Scholar
• Richards DA, Boehm KA, Waterhouse DM et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a Phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol. 17(7), 1096–1102 (2006).
   Google Scholar
• Friess H, Langrehr JM, Oettle H et al. A randomized multicenter Phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6, 285 (2006).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27(13), 2231–2237 (2009).
   PubMed Web of Science ®Google Scholar
• Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs, 11(8), 635–638 (2000).
   Google Scholar
• Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res. 30(7), 2905–2909 (2010).
   Google Scholar
• Oh SY, Kim HJ, Kim TH et al. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer. Invest. New Drugs, 28(3), 343–349 (2010).
   Google Scholar
• Yoo C, Hwang JY, Kim JE et al. A randomised Phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br. J. Cancer, 101(10), 1658–1663 (2009).
   Google Scholar
• Ko AH, Venook AP, Bergsland EK et al. A Phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 66(6), 1051–1057 (2010).
   Google Scholar
• Wolpin BM, Hezel AF, Abrams T et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 27(2), 193–198 (2009).
   Google Scholar
• O’Reilly EM, Niedzwiecki D, Hall M et al. A cancer and leukemia group B Phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist, 15(12), 1310–1319 (2010).
   Google Scholar